D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Benzinga · 4d ago
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.